Gosset Alvine Pharmaceuticals General Information
Alvine Pharmaceuticals was a private, clinical-stage biopharmaceutical company focused on developing biologic therapeutics for autoimmune and gastrointestinal disorders. Its lead candidate, ALV003—a combination of two gluten-specific recombinant proteases—was developed to degrade gluten in the digestive tract and treat celiac disease. The drug reached Phase 2b clinical trials in one of the largest studies conducted for celiac patients maintained on a gluten-free diet. Results from earlier studies showed that ALV003 could diminish gluten-induced intestinal injury in well-controlled celiac patients. In late-stage development planning as of its last public updates around late 2013–2014, the company's non-cash assets were acquired by ImmunogenX™ in 2016 and there have been no further independent developments reported since then.[7]
Contact Information
United States
Drug Pipeline
Key Partnerships
Investors include AbbVie, Sofinnova Ventures, InterWest Partners, Prospect Venture Partners, Panorama Capital among others; no major pharma co-development partnerships disclosed.[2]
Alvine Pharmaceuticals Funding
No funding data available